- Home
- SRG vs ABEO Comparison
SRG vs ABEO Comparison
Compare SRG & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRG | ABEO |
|---|---|---|
| Founded | 2014 | 1974 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.7M | 280.2M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | SRG | ABEO |
|---|---|---|
| Price | $2.69 | $4.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.75 |
| AVG Volume (30 Days) | 180.5K | ★ 1.4M |
| Earning Date | 05-14-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | N/A | $112.53 |
| P/E Ratio | ★ N/A | $4.29 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $2.43 | $3.93 |
| 52 Week High | $4.56 | $7.54 |
Technical Indicators
Market Signals| Indicator | SRG | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 31.23 | 32.62 |
| Support Level | N/A | $4.00 |
| Resistance Level | $2.97 | $5.62 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 8.06 | 2.44 |
Price Performance
Historical ComparisonAbout SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.